#USA #Scottsdale #Oncology Trials #Imaging Endpoints #AIRC System

Imaging Endpoints Innovates with Revolutionary AI System in Oncology

On September 11, 2025, Imaging Endpoints (IE), a front-runner in imaging technologies and services for oncology clinical trials, announced the submission of a provisional patent for its cutting-edge AI-driven Imaging Review Charter (IRC) system, known as the AIRC System™. This advancement aims to set new benchmarks in the realm of clinical trials by enhancing the process of creating personalized IRCs.

A Commitment to Precision in Oncology Imaging

The AIRC System is designed to address long-standing challenges in the design of imaging trials. By improving how data is processed, IE allows for intelligent and customized modifications to standard oncology criteria. This is done while ensuring compliance with current regulatory requirements from the FDA, EMA, and other global agencies, reinforcing the system's reliability and credibility.

Imaging Endpoints has established a strong reputation in the industry, boasting an impressive 95% success rate in securing market authorization with over 200 regulatory approvals under its belt. The dedication to refining imaging acquisition and analysis is a hallmark of IE, ensuring that clinical trials utilize the most precise criteria possible.

Key Features of the AIRC System

The AIRC System integrates several key features that differentiate it in the market:

1. Dynamic Personalization: The system incorporates a personalization module that draws data from industry standards, published oncology criteria, IE's customized analysis library, and study protocols. This allows for the generation of dynamic IRC documents tailored specifically to the requirements of each trial.

2. Optimized Criteria: With the largest dataset and best methodologies at its disposal, the AIRC System identifies necessary clarifications or modifications of specific criteria to optimize imaging acquisition and analysis for each unique trial setup.

3. Enhanced Regulatory Compliance: By integrating recent guidelines and findings from regulatory bodies like the FDA, the AIRC System optimizes compliance, ensuring that enhancements made to criteria are clearly defined and documented in accordance with regulatory standards.

4. Increased Efficiency: Utilizing AI, the system compiles and integrates pertinent data for examination by medical and operational experts at IE, expediting the trial setup process and ensuring highly reliable results.

A Future-Oriented Vision

Doug Dean Burkett, the CEO of Imaging Endpoints, highlighted the significance of this development: “For over 15 years, IE has been at the forefront of imaging services in oncology. This patent filing marks a notable milestone in our commitment to connect imaging to cures.” The AIRC System’s AI optimization is set to boost efficiency in oncology trials, while also solidifying IE’s leadership position in the industry.

About Imaging Endpoints

Imaging Endpoints is committed to their vision of connecting imaging to healing. With an impeccable global inspection record and remarkable track record in market authorization, the company has proven its effectiveness in supporting successful regulatory submissions worldwide. Their commitment to quality, innovation, rapid turnaround times, and operational excellence has established IE as a leading name in oncological imaging.

With strategically located offices across six countries, including Arizona, Massachusetts, the UK, Netherlands, Switzerland, India, and China, Imaging Endpoints is poised to continue its mission in the oncology space with the AIRC System and other innovations.

For media inquiries or to obtain a copy of their recent white paper on optimizing criteria, please contact [email protected].